Skip to main content

Peer Review reports

From: Neoadjuvant inetetamab and pertuzumab with taxanes and carboplatin (TCbIP) In locally advanced HER2-positive breast cancer: a prospective cohort study with propensity-matched analysis

Original Submission
24 Apr 2024 Submitted Original manuscript
9 Jun 2024 Reviewed Reviewer Report
25 Jun 2024 Reviewed Reviewer Report
2 Jul 2024 Author responded Author comments - Qiao Li
3 Jul 2024 Author responded Author comments - Qiao Li
Resubmission - Version 2
2 Jul 2024 Submitted Manuscript version 2
6 Jul 2024 Author responded Author comments - Qiao Li
Resubmission - Version 3
6 Jul 2024 Submitted Manuscript version 3
10 Jul 2024 Author responded Author comments - Qiao Li
Resubmission - Version 4
10 Jul 2024 Submitted Manuscript version 4
12 Jul 2024 Author responded Author comments - Qiao Li
Resubmission - Version 5
12 Jul 2024 Submitted Manuscript version 5
16 Jul 2024 Author responded Author comments - Qiao Li
Resubmission - Version 6
16 Jul 2024 Submitted Manuscript version 6
Publishing
17 Jul 2024 Editorially accepted
22 Jul 2024 Article published 10.1186/s12885-024-12654-3

You can find further information about peer review here.

Back to article page